Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LongeveronLGVN +1.40%45 Days Payable is 243.79 as of Mar. 2026, which is 14% below its 10-year median of 283.63. GuruFocus rates LGVN with a GF Score™ of 45/100 and a GF Value™ of $0.38 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 702 Biotechnology companies, Longeveron ranks better than 79.06% on this metric.
Longeveron's average Accounts Payable for the
three
months ended in Mar. 2026 was $0.36 Mil. Longeveron's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.13 Mil.
Hence, Longeveron's Days Payable for the
three
months ended in Mar. 2026 was 243.79.
The historical rank and industry rank for Longeveron's Days Payable or its related term are showing as below:
LGVN'
s Days Payable Range Over the Past 10 Years
Min: 113.22 Med: 283.63 Max: 893.43
Current: 492.92
During the past 8 years, Longeveron's highest Days Payable was 893.43. The lowest was 113.22. And the median was 283.63.
LGVN's Days Payable is ranked better than 79.06% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs LGVN: 492.92
Longeveron's Days Payable
increased
from Mar. 2025 (200.58) to Mar. 2026 (243.79).
It may suggest that Longeverondelayed paying its suppliers.
Longeveron Days Payable Related Terms
Longeveron Days Payable Historical Data
* Premium members only.
The historical data trend for Longeveron's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Longeveron's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Longeveron Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Longeveron's Days Payable distribution charts can be found below:
* The bar in red indicates where Longeveron's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Longeveron's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longeveron (LGVN) has a Days Payable of 243.79 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Longeveron and its competitors. This is 14% below median its historical median of 283.63. Over the past decade, Longeveron's Days Payable has ranged from 113.22 to 893.43. According to the industry distribution chart, Longeveron ranks #147 out of 702 companies in the Biotechnology industry, placing it in the top 20.9%.
Is Longeveron's Days Payable too high?
Longeveron's current Days Payable of 243.79 is 14% below median its 10-year median of 283.63. Over the past 10 years, this metric has ranged from a low of 113.22 to a high of 893.43. The Biotechnology industry median Days Payable is 113.10. Longeveron's value of 243.79 is 115.6% above this industry median. Based on the distribution chart, Longeveron ranks #147 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Longeveron has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Longeveron's Days Payable compare to MRKR and PLUR?
According to the Biotechnology industry distribution chart, Longeveron ranks #147 out of 702 companies for Days Payable. This places Longeveron in the top 21% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.10. Longeveron's value of 243.79 is 115.6% above this benchmark. Historically, Longeveron's own Days Payable has ranged from 113.22 to 893.43 over the past decade. While the company's 10-year median is 283.63 vs. the industry median of 113.10, Longeveron has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Longeveron's current Days Payable of 243.79 is 115.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Longeveron and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Longeveron's current Days Payable is 243.79, which is 14% below median its own 10-year median of 283.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longeveron stock overvalued right now?
Based on GuruFocus' analysis, Longeveron (LGVN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.38, compared to a current price of $0.61 — trading 60.8% above its estimated fair value. The current Days Payable is 243.79, which is 14% below median its 10-year median of 283.63 and 115.6% above the Biotechnology industry median of 113.10. Longeveron's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Longeveron (LGVN), the current Days Payable is 243.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Longeveron (LGVN) Overvalued in 2026?
Based on GuruFocus' analysis, Longeveron stock appears to be overvalued.
The current stock price of $0.61 is trading 60.8% above its estimated GF Value™ of $0.38.
GuruFocus considers Longeveron to be Significantly Overvalued.
Key valuation signals for LGVN:
Days Payable: 243.79 (14% below median its 10-year median of 283.63)
GF Value™: $0.38 vs. price of $0.61 (60.8% above fair value)
Industry Position: 115.6% above the Biotechnology median (#147 of 702)
No single metric tells the full story. See the LGVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
45GF Score
Get the complete analysis for LGVN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LGVN has been successfully added to your 
